Buy-rated reports

588 tickers rated Buy
Ranks this page's recent reports by score.
MDA Space Ltd.
MDA·Industrials
A ★★★★Buy
Current$35.26
Target$44.80
Return+27.1%
Aug 19, 2026

MDA is a highly profitable, wide-moat space infrastructure prime poised for accelerating revenue through its $4.0 billion backlog and aggressive global M&A, though investors must remain hyper-vigilant regarding serial equity dilution and complex cross-border integration risks.

Score
93
DLocal Limited
DLO·Technology
A ★★★★Buy
Current$13.91
Target$16.95
Return+21.9%
Aug 19, 2026

dLocal is an immensely profitable, fast-growing tollbooth monopolizing enterprise payment routing into emerging markets, trading at a deeply depressed free cash flow multiple, though investors must tolerate persistent take-rate compression and the intense psychological drag of large-scale founder divestitures.

Score
86
Oceaneering International, Inc.
OII·Energy
A ★★★★Buy
Current$54.11
Target$68.16
Return+26.0%
Aug 19, 2026

Oceaneering represents an exceptionally undervalued opportunity to acquire a cash-gushing, market-dominant subsea robotics franchise aggressively transforming into a premier aerospace and defense contractor, though investors must continuously monitor the vulnerability of offshore capital expenditures to severe commodity price fluctuations.

Score
90
Pattern Group Inc.
PTRN·Consumer Discretionary
A ★★★★Buy
Current$20.67
Target$29.00
Return+40.3%
Aug 19, 2026

Pattern is the rapidly scaling, AI-driven tollbooth of global multi-channel e-commerce, trading at a deep discount to pure-play software peers, though investors must tacticaly navigate the near-term turbulence of post-IPO insider equity unlocks.

Score
90
Celcuity Inc.
CELC·Healthcare
A ★★★★Buy
Current$92.00
Target$156.39
Return+69.9%
Aug 19, 2026

Celcuity is poised to dominate a $5 billion breast cancer niche with its newly approved, structurally superior pan-PI3K/mTOR inhibitor, offering explosive 2027 revenue upside, provided management flawlessly executes its commercial launch.

Score
87
PJT Partners Inc.
PJT·Financials
A ★★★★Buy
Current$174.40
Target$188.00
Return+7.8%
Aug 19, 2026

PJT Partners is a wildly profitable, capital-light advisory powerhouse poised to capture massive market share in both M&A and restructuring, though investors must remain hyper-vigilant regarding the firm's absolute dependence on retaining elite human capital in a cutthroat hiring market.

Score
87
Marex Group Limited
MRX·Financials
A ★★★★Buy
Current$71.06
Target$90.00
Return+26.7%
Aug 19, 2026

Marex is an exceptionally profitable, rapidly compounding financial infrastructure tollbooth trading at a wildly discounted 11.5x forward multiple, though investors must remain deeply vigilant against the mechanical compression of net interest income if central banks aggressively slash global interest rates.

Score
85
United Community Banks, Inc.
UCB·Financials
A ★★★★Buy
Current$36.63
Target$42.00
Return+14.7%
Aug 18, 2026

United Community is a high-quality regional franchise benefiting from massive Southeastern demographic tailwinds and expanding margins, offering a compelling valuation and imminent share repurchases, though investors must monitor the transitional execution risks tied to its ongoing M&A integrations and asset divestitures.

Score
88
Broadstone Net Lease, Inc.
BNL·Real Estate
A ★★★★Buy
Current$21.39
Target$23.40
Return+9.4%
Aug 18, 2026

Broadstone Net Lease pairs a deeply undervalued, inflation-protected triple-net portfolio with a highly accretive industrial development pipeline, though investors must tolerate near-term leverage spikes and the execution risk inherent in mega-project construction.

Score
88
Octave Intelligence plc
OCTV·Technology
A ★★★★Buy
Current$18.91
Target$32.50
Return+71.9%
Aug 18, 2026

Octave is a highly cash-generative, mission-critical infrastructure software monopoly trading at an irrationally steep discount due to post-spin accounting noise, though investors must tolerate near-term revenue friction as the company aggressively phases out legacy perpetual licenses in favor of cloud subscriptions.

Score
88
LivaNova PLC
LIVN·Healthcare
A ★★★★Buy
Current$81.48
Target$91.35
Return+12.1%
Aug 18, 2026

LivaNova is a deeply entrenched medical device compounder perfectly positioned to harvest explosive margin expansion from recent Medicare reimbursement hikes, though investors must tolerate near-term execution risk surrounding its critical supply chain scale-up and sleep apnea regulatory filings.

Score
86
AZZ Inc.
AZZ·Industrials
A ★★★★Buy
Current$151.35
Target$165.00
Return+9.0%
Aug 18, 2026

AZZ is the dominant, cash-gushing tollbooth for North America's infrastructure and grid modernization supercycle, boasting massive pricing power and a pristine balance sheet, though investors must remain hyper-vigilant regarding its exposure to cyclical construction downturns and zinc price volatility.

Score
88
KBR, Inc.
KBR·Industrials
A ★★★★Buy
Current$38.37
Target$51.87
Return+35.2%
Aug 18, 2026

KBR is a highly misunderstood, cash-gushing technology and defense powerhouse trading at a severe conglomerate discount, offering an exceptional value-unlock catalyst via its 2027 spin-off, provided the balance sheet can navigate the frictional costs of the separation.

Score
87
Veracyte, Inc.
VCYT·Healthcare
A ★★★★Buy
Current$42.08
Target$54.60
Return+29.8%
Aug 18, 2026

Veracyte commands a highly profitable moat in oncology diagnostics with its Decipher and Afirma franchises, trading at an attractive valuation, though investors must monitor the scale-up risks of its new Prosigna and TrueMRD launches amid shifting clinical guidelines.

Score
89
Excelerate Energy, Inc.
EE·Energy
A ★★★★Buy
Current$36.63
Target$43.66
Return+19.2%
Aug 18, 2026

Excelerate has masterfully transformed into an integrated, cash-printing global LNG utility trading at a deeply misunderstood growth multiple, though investors must stomach the inherent geopolitical volatility of its emerging-market sovereign counterparties.

Score
86
BBB Foods Inc.
TBBB·Consumer Staples
A ★★★★Buy
Current$49.20
Target$57.99
Return+17.9%
Aug 18, 2026

BBB Foods is an unstoppable, self-funding retail juggernaut systematically capturing the massive Mexican hard-discount market through flawless logistical execution, though investors must tolerate persistent GAAP net losses driven by aggressive share-based dilution.

Score
87
CNX Resources Corporation
CNX·Energy
A ★★★★Buy
Current$35.72
Target$38.48
Return+7.7%
Aug 18, 2026

CNX is a hyper-efficient, free-cash-flow-generating machine executing a masterful share buyback program while unlocking new clean-energy tax credits, though investors must tolerate the unavoidable cyclical volatility of the currently oversupplied Appalachian natural gas basin.

Score
88
Kontoor Brands, Inc.
KTB·Consumer Discretionary
A ★★★★Buy
Current$84.90
Target$98.05
Return+15.5%
Aug 18, 2026

Kontoor Brands is aggressively upgrading its margin and growth profile by swapping legacy denim for premium outdoor apparel, executing a massive $400M share buyback that makes the stock a screaming value, though investors must monitor execution risks surrounding stranded corporate costs and escalating U.S. import tariffs.

Score
93
ServisFirst Bancshares, Inc.
SFBS·Financials
A ★★★★Buy
Current$90.53
Target$105.00
Return+16.0%
Aug 18, 2026

ServisFirst Bancshares operates a highly efficient, branch-lite commercial banking model that delivers peer-leading returns on equity and assets, making it a robust quality compounder despite the typical credit and liquidity risks associated with regional banking.

Score
88
Hamilton Lane Incorporated
HLNE·Financials
A ★★★★Buy
Current$104.24
Target$135.54
Return+30.0%
Aug 18, 2026

Hamilton Lane operates as the premier, indispensable toll-collector of the expanding private markets ecosystem, trading at an undeniable cash-flow discount despite boasting 30%+ ROE, though investors must navigate the cyclical lumpiness of its massive, yet macro-dependent, carried interest realizations.

Score
92
Definium Therapeutics, Inc.
DFTX·Healthcare
A ★★★★Buy
Current$42.63
Target$73.00
Return+71.2%
Aug 18, 2026

Definium Therapeutics is poised to revolutionize psychiatric care with its de-risked Phase 3 psychedelic candidate DT120, backed by a formidable $1.1 billion cash runway, though investors must navigate the execution risks of regulatory approval and commercial rollout.

Score
87
Terex Corporation
TEX·Industrials
A ★★★★Buy
Current$67.92
Target$86.00
Return+26.6%
Aug 18, 2026

Terex is transforming into a higher-margin, lower-cyclicality compounder through its REV Group merger and ESG acquisition, though tariff pressures on its legacy Aerials business remain a near-term hurdle.

Score
85
Nelnet, Inc.
NNI·Financials
A ★★★★Buy
Current$127.79
Target$140.00
Return+9.6%
Aug 18, 2026

Nelnet is an exceptional capital-compounding machine disguised as a boring student loan servicer, using massive cash flows from an amortizing legacy portfolio to fund highly profitable tech and banking ventures at a deep discount to its true sum-of-the-parts intrinsic value.

Score
86
FTI Consulting, Inc.
FCN·Industrials
A ★★★★Buy
Current$151.85
Target$185.60
Return+22.2%
Aug 17, 2026

FTI Consulting operates as an elite, wide-moat tollbooth for global corporate crises and regulatory friction, currently trading at a profound discount to peers due to temporary margin noise, while aggressively utilizing its massive cash flows to systematically shrink its outstanding share count.

Score
87